Session XIX: Predicting and Managing Rare Toxicities in Patients With GI Cancers

Chair(s)

• 

  Shouki Bazarbashi, MBBS

  King Faisal Specialist Hospital and Research Center-Riyadh
  Riyadh, Saudi Arabia
• 

  Elena Elez, Sr., MD PhD

  Vall Hebron University Hospital
  Barcelona, Spain
• 

  Demetris Papamichael, MB BS FRCP

  Bank of Cyprus Oncology Centre
  Nicosia, Cyprus

Presentations:

• 18:30 – 18:40 CEST

  O-9: Health‑related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
  

  Abstract Presenter: Gerald Prager, MD – Medizinische Universität Wien
• 18:30 – 18:50 CEST

  O-10: Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C)
  

  Abstract Presenter: Markus Moehler, MD – Universitätsmedizin Mainz
• 18:50 – 19:15 CEST

  Keynote Lecture: Toxicity Management - Nausea and Vomiting
  

  Speaker: Matti Aapro, MD – Clinique de Genolier